Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.82M | -19.80M | -14.61M | -15.43M | -15.09M |
| Total Depreciation and Amortization | 102.00K | 102.00K | 110.00K | 114.00K | 128.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.20M | 3.33M | 2.96M | 4.56M | 3.84M |
| Change in Net Operating Assets | -1.63M | 3.24M | 612.00K | 759.00K | -1.94M |
| Cash from Operations | -18.15M | -13.13M | -10.93M | -9.99M | -13.06M |
| Capital Expenditure | -13.00K | -24.00K | -23.00K | -21.00K | -43.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.92M | 10.39M | 13.85M | 5.07M | 19.16M |
| Cash from Investing | -30.93M | 10.37M | 13.83M | 5.05M | 19.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 58.03M | -- | -- | -- | -- |
| Repurchase of Common Stock | -250.00K | -162.00K | 0.00 | -9.00K | -275.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -2.37M | -3.04M | -- | -- |
| Cash from Financing | 57.78M | -2.53M | -3.04M | -9.00K | -275.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.70M | -5.30M | -146.00K | -4.96M | 5.79M |